Trials / Completed
CompletedNCT05100199
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 328 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OnabotulinumtoxinA X | Injection |
| DRUG | Placebo | Injection |
Timeline
- Start date
- 2021-10-06
- Primary completion
- 2022-12-02
- Completion
- 2022-12-02
- First posted
- 2021-10-29
- Last updated
- 2025-09-09
- Results posted
- 2025-09-09
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05100199. Inclusion in this directory is not an endorsement.